The antiviral activity of dideoxycytidine.
2',3'-Dideoxycytidine (ddc) is a 2',3'-dideoxypyrimidine nucleotide which has been shown to be active against human immunodeficiency virus type 1 (HIV-1) in cell cultures. This article reviews some of the laboratory studies with this antiviral compound, and available pharmacokinetic and toxicity data from phase 1 studies of ddc alone and in alternation with zidovudine in patients with AIDS and ARC. Though ddc has potent activity against HIV-1 in vitro, serious toxic effects seen in phase 1 studies warrant continuation of trials to explore lower dosage regimens, alternation with zidovudine and intermittent therapy.
Jeffries
D J
DJ
Division of Virology, St. Mary's Hospital Medical School, Paddington, London, UK.
D000818:Animals; D000998:Antiviral Agents / Q000009:adverse effects / Q000493:pharmacokinetics; D015224:Dideoxynucleosides / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D004341:Drug Evaluation; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D016047:Zalcitabine
D000998:Antiviral Agents; D015224:Dideoxynucleosides; D016047:Zalcitabine